Jackson S R, Tweeddale M G, Barnett M J, Spinelli J J, Sutherland H J, Reece D E, Klingemann H G, Nantel S H, Fung H C, Toze C L, Phillips G L, Shepherd J D
Division of Hematology, Vancouver Hospital and Health Sciences Center, British Columbia Cancer Agency, University of British Columbia, Canada.
Bone Marrow Transplant. 1998 Apr;21(7):697-704. doi: 10.1038/sj.bmt.1701158.
The role of ICU support in BMT patients is controversial. In an era of constrained resources, the use of prognostic factors predicting outcome may be helpful in identifying patients who are most likely (or unlikely) to benefit from this intervention. We attempted to define the survival of patients admitted to ICU following autologous or allogeneic BMT and to identify those factors important in determining patient outcome. A retrospective study of all adult BMT recipients admitted to intensive care over a 6 year study period was performed to determine overall and prognostic indicators of poor outcome. Pre-treatment, pre-ICU admission and ICU admission data were analyzed to identify factors predicting long-term survival. 116 patients were admitted to ICU on 135 separate occasions with the primary reasons for admission being respiratory failure (66%), sepsis associated with hypotension (10%), and cardiorespiratory failure (8%). No pre-ICU characteristics were predictive of survival. Univariate analysis identified the number of support measures required, the need for ventilation or hemodynamic support, the APACHE II score, the year of ICU admission and the serum bilirubin as significant predictors of post-discharge survival. On multivariate analysis the year of ICU admission, the need for hemodynamic support and the serum bilirubin remained significant. The APACHE II score significantly underestimated survival in the 46% of patients with scores less than 35, and could only be used to predict 100% mortality when it exceeded 45. Twenty-three percent of all BMT patients admitted to the ICU and 17% of ventilated patients survived to hospital discharge. Of the 27 patients surviving to leave hospital, 16 remain alive with a median follow-up of 4.2 years and a mean Karnofsky performance status of 90. Although mortality in BMT recipients admitted to ICU is high our results indicate that intensive care support can be lifesaving and that the outcome in patients requiring ventilation and ICU support may not be as poor as has been previously reported. No single variable was identified which could be used to predict futility but patients requiring both hemodynamic support and mechanical ventilation, and those with an APACHE II score greater than 45 have a very poor prognosis and are unlikely to benefit from lengthy ICU support.
重症监护病房(ICU)支持在骨髓移植(BMT)患者中的作用存在争议。在资源受限的时代,使用预测预后的因素可能有助于识别最有可能(或不太可能)从这种干预中获益的患者。我们试图确定自体或异基因BMT后入住ICU患者的生存率,并确定那些对决定患者预后至关重要的因素。对在6年研究期间入住重症监护病房的所有成年BMT受者进行了一项回顾性研究,以确定总体和不良预后的预测指标。分析预处理、ICU入院前和ICU入院数据,以确定预测长期生存的因素。116例患者在135个不同时间入住ICU,主要入院原因是呼吸衰竭(66%)、伴有低血压的脓毒症(10%)和心肺衰竭(8%)。ICU入院前的特征均不能预测生存。单因素分析确定所需支持措施的数量、通气或血流动力学支持的需求、急性生理与慢性健康状况评分系统(APACHE II)评分、ICU入院年份和血清胆红素是出院后生存的重要预测因素。多因素分析显示,ICU入院年份、血流动力学支持的需求和血清胆红素仍然具有显著性。在APACHE II评分低于35分的患者中,有46%的患者其生存情况被该评分显著低估,只有当评分超过45分时,才能用于预测100%的死亡率。所有入住ICU的BMT患者中有23%以及通气患者中有17%存活至出院。在存活出院的27例患者中,16例仍然存活,中位随访时间为4.2年,卡氏功能状态评分平均为90分。尽管入住ICU的BMT受者死亡率很高,但我们的结果表明,重症监护支持可以挽救生命,并且需要通气和ICU支持的患者的预后可能并不像之前报道的那么差。没有发现单一变量可用于预测治疗无效,但需要血流动力学支持和机械通气的患者以及APACHE II评分大于45分的患者预后非常差,不太可能从长时间的ICU支持中获益。